The FDA approved BridgeBio’s Nulibry (fosdenopterin), once known as ALXN1101, on Friday to treat molybdenum cofactor deficiency type A, an autosomal recessive, inborn error of metabolism caused by mutations in the molybdenum cofactor synthesis 1 gene (MOCS1).
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,